UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
[x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended March 31, 2000 or
[_] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the transition period from _______________ to ________________
COMMISSION FILE NUMBER 000-30231
TANOX, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 76-0196733
(State or Other Jurisdiction of (IRS Employer
Incorporation or Organization) Identification No.)
10301 STELLA LINK, SUITE 110
HOUSTON, TEXAS 77025-5497
(Address of Principal Executive Offices) (Zip Code)
(713) 664-2288
(Registrant's Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
(1) Yes [X] No [ ] (2) Yes [ ] No [X]
As of May 11, 2000, the registrant had 42,541,123 shares of Common Stock
issued and outstanding.
TANOX, INC.
FORM 10-Q
INDEX
PART I. CONSOLIDATED FINANCIAL INFORMATION....................................3
Item 1. Condensed Consolidated Balance Sheets at March 31, 2000
(Unaudited) and December 31, 1999..................................3
Condensed Consolidated Statements of Operations and
Comprehensive Net Loss (Unaudited) for the three months
ended March 31, 2000 and the three months ended March 31, 1999.....4
Condensed Consolidated Statements of Cash Flows (Unaudited) for
the three months ended March 31, 2000 and the three months ended
March 31, 1999.....................................................5
Notes to Condensed Consolidated Financial Statements...............6
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations..............................................7
Item 3. Quantitative and Qualitative Disclosures About Market Risk........11
PART II. OTHER INFORMATION.................................................11
Item 2. Changes In Securities and Use of Proceeds.........................12
Item 6. Exhibits and Reports on Form 8-K..................................12
SIGNATURES ...................................................................15
2
PART I.
CONSOLIDATED FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL INFORMATION
Tanox, Inc.
Condensed Consolidated Balance Sheets
MARCH 31,
2000 DECEMBER 31,
(UNAUDITED) 1999
------------ ------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents .................................. $ 28,864,000 $ 44,242,000
Short-term investments ..................................... 15,428,000 3,012,000
Accounts receivable ........................................ 225,000 125,000
Interest receivable ........................................ 438,000 414,000
Income taxes receivable .................................... 132,000 132,000
Prepaid expenses ........................................... 167,000 114,000
------------ ------------
Total current assets ................................... 45,254,000 48,039,000
PROPERTY AND EQUIPMENT:
Laboratory and office equipment ............................ 9,423,000 9,369,000
Leasehold improvements ..................................... 2,095,000 2,102,000
Furniture and fixtures ..................................... 119,000 119,000
------------ ------------
11,637,000 11,590,000
Accumulated depreciation and amortization .................. (4,849,000) (4,577,000)
------------ ------------
Net property and equipment ............................. 6,788,000 7,013,000
OTHER ASSETS:
Deferred offering expenses .................................. 1,200,000 --
Other assets, net of accumulated amortization of
$67,000 and $59,000, respectively ......................... 255,000 276,000
------------ ------------
1,455,000 276,000
Total assets ........................................... $ 53,497,000 $ 55,328,000
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable ........................................... $ 2,814,000 $ 874,000
Accrued liabilities ........................................ 2,030,000 947,000
Accrued arbitration award .................................. 3,500,000 3,500,000
------------ ------------
Total current liabilities .............................. 8,344,000 5,321,000
NOTE PAYABLE TO RELATED PARTY .................................. 10,000,000 10,000,000
STOCKHOLDERS' EQUITY:
Preferred stock, $.01 par value; 10,000,000 shares
authorized; none outstanding ............................ -- --
Common stock, $.01 par value; 120,000,000 shares
authorized; 33,973,123 shares in 2000 and
33,324,402 shares in 1999 issued and outstanding ........ 340,000 333,000
Additional paid-in capital ................................. 73,133,000 71,701,000
Deferred compensation ...................................... (1,003,000) (651,000)
Loans receivable from employees ............................ (1,086,000) (1,086,000)
Other comprehensive income, cumulative translation adjustment 197,000 171,000
Retained deficit .......................................... (36,428,000) (30,461,000)
------------ ------------
STOCKHOLDERS' EQUITY ......................................... 35,153,000 40,007,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY ................... $ 53,497,000 $ 55,328,000
============ ============
See accompanying notes to condensed
consolidated financial statements.
3
Tanox, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Net Loss
(Unaudited)
FOR THE THREE MONTHS ENDED,
--------------------------------
MARCH 31, 2000 MARCH 31, 1999
-------------- --------------
REVENUES:
Development agreement with related party ........... $ 1,000 $ 34,000
Other development agreements and licensing fees .... 148,000 123,000
-------------- --------------
Total revenues .................................. 149,000 157,000
OPERATING COSTS AND EXPENSES:
Research and development ........................... 5,403,000 2,415,000
General and administrative ......................... 1,191,000 863,000
-------------- --------------
Total operating costs and expenses .............. 6,594,000 3,278,000
LOSS FROM OPERATIONS ................................. (6,445,000) (3,121,000)
OTHER INCOME (EXPENSE):
Interest income .................................... 716,000 394,000
Interest expense ................................... (200,000) (181,000)
Other .............................................. (38,000) (48,000)
-------------- --------------
Total other income ............................... 478,000 165,000
LOSS BEFORE INCOME TAXES ............................. (5,967,000) (2,956,000)
(Provision) for income taxes ....................... -- (2,000)
-------------- --------------
NET LOSS ............................................. $ (5,967,000) $ (2,958,000)
============== ==============
NET LOSS PER SHARE
Basic ............................................ $ (0.18) $ (0.10)
Diluted .......................................... $ (0.18) $ (0.10)
SHARES USED IN COMPUTING NET LOSS PER SHARE
Basic ............................................ 33,527,000 29,310,000
Diluted .......................................... 33,527,000 29,310,000
COMPREHENSIVE NET LOSS
Net loss ........................................... $ (5,967,000) $ (2,958,000)
Foreign currency translation adjustment ............ 26,000 41,000
-------------- --------------
TOTAL COMPREHENSIVE NET LOSS ......................... $ (5,941,000) $ (2,917,000)
============== ==============
See accompanying notes to condensed consolidated
financial statements.
4
Tanox, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
FOR THE THREE MONTHS ENDED,
--------------------------------
MARCH 31, 2000 MARCH 31, 1999
-------------- --------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ................................................ $ (5,967,000) $ (2,958,000)
Adjustments to reconcile net loss to net cash
used in operating activities-
Depreciation and amortization ....................... 287,000 239,000
Amortization of deferred compensation related
to stock options .................................. 144,000 76,000
Changes in operating assets and liabilities-
(Increase) decrease in accounts and interest
receivables ....................................... (124,000) 29,000
(Increase) in prepaid expenses ...................... (53,000) (71,000)
(Increase) decrease in accounts payable and
accrued liabilities ............................... 3,023,000 (308,000)
-------------- --------------
Net cash used for operations ..................... (2,690,000) (2,993,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments ...................... (15,428,000) (5,900,000)
Maturity of short-term investments ...................... 3,012,000 2,491,000
Purchases of property and equipment ..................... (54,000) (104,000)
Decrease in other assets ................................ 13,000 18,000
-------------- --------------
Net cash used for investing activities ........... (12,457,000) (3,495,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Deferred offering expenses .............................. (1,200,000) --
Proceeds from the issuance of stock ..................... 943,000 --
-------------- --------------
Net cash generated by financing activities ....... (257,000) --
IMPACT OF EXCHANGE RATES ON CASH ........................ 26,000 41,000
CHANGE IN CASH AND CASH EQUIVALENTS ..................... (15,378,000) (6,447,000)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD .......... 44,242,000 28,352,000
-------------- --------------
CASH AND CASH EQUIVALENTS, END OF PERIOD ................ $ 28,864,000 $ 21,905,000
============== ==============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes ............................ $ -- $ 2,000
See accompanying notes to condensed
consolidated financial statements.
5
TANOX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2000
(UNAUDITED)
NOTE 1. BASIS OF CONSOLIDATION
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and in accordance with the instructions to Form 10-Q and
Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all normal,
recurring adjustments considered necessary for fair presentation have been
included. These condensed consolidated interim financial statements and notes
thereto should be considered in conjunction with the Company's Consolidated
Financial Statements and accompanying notes for the year ended December 31, 1999
which were included in the Company's Registration Statement on Form S-1
(Registration No. 333-96025). Results for the interim period ended March 31,
2000 are not necessarily indicative of the results that may be expected for the
year ending December 31, 2000.
NOTE 2. LICENSE AGREEMENT WITH PROTEIN DESIGN LABS, INC.
During March 2000, Tanox entered into an agreement with Protein Design Labs,
Inc. ("PDL") to acquire the right to take non-exclusive licenses to patents and
patent applications owned by PDL for up to four of the Company's antibodies. Per
the agreement, Tanox agreed to pay initial license fees to PDL of $2.5 million,
in addition to $1.5 million that was previously paid to PDL in 1998 under a
prior licensing agreement. Tanox also agreed to pay up to $4.0 million ($1.0
million per antibody), plus maintenance fees, to PDL if Tanox exercises its
option to license all four antibodies. In addition, Tanox agreed to pay
royalties on future sales if a product using the PDL technology is successfully
commercialized. During the first quarter of 2000, Tanox recorded a research and
development expense of $2.5 million, representing the cost of the initial option
payment.
NOTE 3. EARNINGS PER SHARE
SFAS No. 128, "Earnings Per Share," requires dual presentation of basic and
diluted earnings per share (EPS). Basic EPS is computed by dividing net income
by the weighted average number of shares of common stock outstanding during the
year. Diluted EPS is computed in the same manner as basic EPS, except that
diluted EPS reflects the potential dilution that would occur if outstanding
options and warrants were exercised. Since Tanox incurred net losses for the
quarters ended March 31, 1999 and 2000, basic and diluted EPS are the same.
NOTE 4. INITIAL PUBLIC OFFERING
On April 12, 2000, Tanox concluded the principal part of its previously
announced initial public offering of common stock, and completed the offering on
May 11, 2000 with the exercise by the underwriters of their over-allotment
option. In the offering, Tanox sold 8,568,000 shares of common stock at $28.50
per share for gross proceeds of approximately $244.2 million, including the
underwriters' over-allotment option. The net proceeds from the offering were
approximately $225.9 million. Both the
6
shares issued and the proceeds of the offering will be reflected in Tanox's
financial results for the three months ended June 30, 2000.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
Tanox identifies and develops therapeutic monoclonal antibodies to address
significant unmet medical needs in the areas of immunology, infectious diseases
and cancer. E25, our most advanced product in development, is an anti-IgE
antibody that we are developing in collaboration with Novartis Pharma AG and
Genentech, Inc. E25 has successfully completed Phase III clinical trials in both
allergic asthma and seasonal allergic rhinitis (hay fever). Based on the results
of these trials, in mid-2000, our collaboration partners intend to file for
marketing approval in the United States and Europe for both indications. In
addition, we are developing a number of monoclonal antibodies to treat other
allergic diseases or conditions, such as severe allergic reactions to peanuts,
autoimmune diseases, HIV and neutropenia.
We currently have no products available for sale and are focusing on product
development, clinical trials and process development. We have incurred
substantial losses since inception and incurred an accumulated deficit through
March 31, 2000, of $36.4 million. We expect to continue to incur substantial
operating losses for the foreseeable future, particularly as we increase our
research and development, manufacturing, clinical trial and administrative
activities. We expect that losses will continue until such time, if ever, that
we generate sufficient revenue from royalties on E25 to cover our expenses.
Historically, we have earned revenues primarily from license fees, milestone
payments and sponsored research under our collaboration agreements. In the
future, we expect our principal revenues will be milestone payments, royalties
and profit-sharing payments from Novartis and Genentech. We may also receive
royalties from Hoffman-La Roche Ltd. should it participate in selling E25 in
Europe. Our revenues will depend particularly on the success of our
collaboration partners in developing, manufacturing, obtaining regulatory
approvals for and marketing E25. Because a substantial portion of our revenues
for the foreseeable future will depend on achieving development and
commercialization milestones, we anticipate that our results of operations will
vary substantially from year to year and even quarter to quarter.
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2000 COMPARED TO THE THREE MONTHS ENDED MARCH 31,
1999
REVENUES. Revenues totaled $149,000 in the first quarter of 2000, essentially
unchanged from $157,000 in the first quarter of 1999. During the first quarter
of 2000, revenues were primarily derived from technology licensing fees and
foreign government research grants. During the first quarter of 1999, revenues
were primarily derived from technology license fees and sponsored research
revenues earned under our agreements with Novartis. The Novartis agreement
accounted for 22% of our revenues in the first quarter of 1999 and less than 1%
of the revenues in the first quarter of 2000.
RESEARCH AND DEVELOPMENT EXPENSES. Research and development expenses increased
to $5.4 million in the first quarter of 2000 from $2.4 million in the first
quarter of 1999, an increase of $3.0 million. This increase was principally due
to a $2.5 million charge in the first quarter of 2000 to acquire the right to
non-exclusive licenses to patents and patent applications owned by Protein
Design Labs, Inc. for up to
7
four of our products in development. The remainder of the increase was due to
increased personnel and expansion of preclinical and clinical development
activities.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative expenses
increased to $1.2 million in the first quarter of 2000 from $0.9 million in the
first quarter of 1999, an increase of $0.3 million. This increase was primarily
attributable to higher expenses for salaries, stock-based compensation,
consulting fees, state franchise taxes and investor relations expenses. These
increases were primarily associated with activities associated with becoming a
public company.
OTHER INCOME. Other income increased to $0.5 million in the first quarter of
2000 from $0.2 million in the first quarter of 1999, an increase of $0.3
million. This increase was principally due to an increase in interest income.
Interest income was significantly higher in the first quarter of 2000, compared
to the first quarter of 1999, due to higher cash balances, as a result of
proceeds from private stock offerings in late 1999, and higher prevailing
interest rates.
NET LOSS. As a result of the above factors, our net loss increased to $6.0
million in the first quarter of 2000 from $3.0 million in the first quarter of
1999.
LIQUIDITY AND CAPITAL RESOURCES
We have financed our operations since inception primarily through collaboration
and grant revenues, sales of equity securities, interest income and equipment
financing agreements. From inception through March 31, 2000, we recognized
approximately $59.4 million in collaboration, grant and other revenues.
Additionally, we have raised approximately $54.9 million from sales of equity
securities and $2.5 million from the exercise of stock options, and we have
earned approximately $9.5 million of interest income. As of March 31, 2000, we
had approximately $44.3 million in cash, cash equivalents and short-term
investments available for working capital.
During the first quarter of 2000, we used $2.7 million to finance our operating
activities. The primary use of cash for operating purposes was our net loss of
$6.0 million, although $0.4 million of this amount was attributable to non-cash
items. In addition, changes in working capital were the primary source of cash
from operating activities during the first quarter of 2000, primarily as a
result of a $3.0 million increase in accounts payable and accrued liabilities.
Investing activities used $12.5 million in the first quarter of 2000, primarily
to purchase short-term investment securities. Financing activities used $0.3
million of cash in the first quarter of 2000, including $1.2 million for
deferred offering costs associated with the initial public offering. This use of
cash was partially offset by $0.9 million of proceeds from the sale of stock
through the exercise of stock options. The combination of the above items
resulted in a cash decrease of $15.4 million during the first quarter of 2000.
On April 12, Tanox concluded the principal part of its previously announced
initial public offering of common stock, at which time we sold 7,500,000 shares
of our common stock at an initial offering price of $28.50. On May 11, 2000,
Tanox completed the offering with the exercise by the underwriters of their
over-allotment option to purchase 1,068,000 shares of our common stock at a
price per share of $28.50. In total, Tanox sold 8,568,000 shares of common stock
in the offering at $28.50 per share for gross proceeds of approximately $244.2
million, including the underwriters' over-allotment option. The net proceeds
from the initial public offering are approximately $225.9 million. Both the
shares issued and the proceeds of the offering will be reflected in Tanox's
financial results for the three months ended June 30, 2000.
8
Our current and anticipated development projects will require substantial
additional capital to complete. We anticipate that the amount of cash we need to
fund operations will grow substantially in the future as our projects move from
research to pre-clinical and clinical development. We also expect that we will
need to expand our administrative, clinical development, facilities and business
development activities to support the future development of our programs and to
support the ongoing requirements of a public company.
From 1994 through 1998, Novartis advanced us $10.0 million, pursuant to a loan
agreement, to finance our new clinical manufacturing facility. The loan bears
interest at the London Interbank Offered Rate, or LIBOR, plus two percent (7.3%
and 8.1% at December 31, 1998 and 1999, respectively). Through December 31,
1999, Novartis has agreed to forgive interest on the loan. For the years 1997,
1998 and 1999, the interest Novartis has forgiven has been reflected as interest
expense and a capital contribution. Although the loan is currently scheduled to
be due in full on December 31, 2005, Novartis may partially or totally forgive
the principal and future interest payments based on the future use of the
facility.
From inception through March 31, 2000, we have invested approximately $11.6
million in property and equipment, primarily to support research and product
development activities and to construct our new clinical manufacturing facility.
We pledged all of the assets of the new clinical manufacturing facility as
security for the Novartis loan.
We agreed to loan some employees up to $1.5 million in April 2000 to pay tax
obligations resulting from their stock option exercises in 1999.
We expect to incur substantial additional capital, research and development,
manufacturing and other costs as we continue to develop our products.
Consequently, we may need to raise substantial additional funds. We expect that
the net proceeds from our public offering, which was consummated in April and
May 2000, together with our existing assets and revenue from operations, will
fund our operations for the next three years. However, our future capital needs
will depend on many factors, including successfully commercializing E25,
receiving payments from our collaboration partners, progress in our research and
development activities, the magnitude and scope of these activities, the
progress and level of unreimbursed costs associated with pre-clinical studies
and clinical trials, the costs and magnitude of product or technology
acquisitions, the cost of preparing, filing, prosecuting, maintaining and
enforcing patent claims and other intellectual property rights, competing
technological and market developments, changes in or terminations of existing
collaboration and licensing arrangements, the establishment of additional
collaboration and licensing arrangements, and manufacturing scale-up costs and
marketing activities, if we undertake those activities. We do not have committed
external sources of funding and we cannot assure that we will be able to obtain
additional funds on acceptable terms, if at all. If adequate funds are not
available, we may be required to:
o delay, reduce the scope of or eliminate one or more of our programs;
o obtain funds through arrangements with collaboration partners or others that
may require us to relinquish rights to technologies, product candidates or
products that we would otherwise seek to develop or commercialize ourselves;
or
o license rights to technologies, product candidates or products on terms that
are less favorable to us than might otherwise be available.
We are currently engaged in litigation and arbitration relating to a fee dispute
with the law firms that represented us in connection with the Genentech
litigation. An arbitration panel issued an award
9
entitling the attorneys to receive approximately $3.5 million, including
interest, payments ranging from 33 1/3% to 40% of the future payments we would
receive from Genentech following product approval, and 10% of the royalties that
we would receive on all sales of anti-IgE products by Genentech and Novartis. We
are contesting this award. During the appeals process, we will either post a
bond or place amounts in escrow to secure payment of the award.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to a variety of risks, including foreign currency exchange
fluctuations and changes in interest rates. In the normal course of business, we
have established policies and procedures to manage these risks.
FOREIGN CURRENCY EXCHANGE RATES. During the first quarter of 2000, our operating
results reflect foreign exchange losses of $38,000 and our balance sheet
reflects a foreign currency translation adjustment of $197,000. We are subject
to foreign currency exchange risk because:
o we invest in our foreign subsidiaries;
o we incur a significant portion of our costs and expenses and a smaller
portion of our revenues in the local currencies of the countries where we
do business; and
o we finance part of the cost of our subsidiaries' operations through dollar
denominated inter-company loans and equity investments that are recorded on
their books in the respective local currencies.
Fluctuations in exchange rates have not had a material impact on our revenues or
costs and expenses, but have affected the value of our equity investments and
inter-company loans. As a result of our international operations and our current
financing approach, fluctuations in exchange rates of the local currencies
versus the U.S. dollar impact our operating results. We are primarily exposed to
gains and losses with respect to Dutch guilders and Taiwan dollars because our
subsidiaries conduct business in these currencies. To date, we have not
implemented a program to hedge our foreign currency risk, but we may do so in
the future.
INTEREST RATE RISK. Cash and short-term investments were approximately $44.3
million at March 31, 2000. These assets were primarily invested in investment
grade commercial paper that we hold to maturity. We do not invest in derivative
securities. Although our portfolio is subject to fluctuations in interest rates
and market conditions, no gain or loss on any security would actually be
recognized in earnings unless we sell the asset. In addition, our loan from
Novartis is based on a premium over LIBOR. As such, if general interest rates
increase, our interest costs will increase.
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS. Some of the information in this
Quarterly Report on Form 10-Q contains forward-looking statements. We typically
identify forward-looking statements by using terms such as "may," "will,"
"should," "could," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential" or "continue" or similar words, although we express some
forward-looking statements differently. You should be aware that actual events
could differ materially from those suggested in the forward-looking statements
due to a number of factors, including:
o the ability to develop safe and efficacious drugs;
o failure to achieve positive results in clinical trials;
o failure to successfully commercialize our products;
o relationships with our collaboration partners;
10
o variability of royalty, license and other revenues;
o ability to enter into future collaboration agreements;
o competition and technological change; and
o existing and future regulations affecting our business.
You should also consider carefully the statements under "Quantitative and
Qualitative Disclosures about Market Risk" and other sections of this Quarterly
Report, which address additional factors that could cause our actual results to
differ from those set forth in the forward-looking statements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
See "Quantitative and Qualitative Disclosures About Market Risk" under "Item 2.
Management's Discussion and Analysis of Financial Condition and Results of
Operations" for quantitative and qualitative disclosures about market risk.
11
PART II
OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
On April 6, 2000, the Securities and Exchange Commission declared
effective our Registration Statement on Form S-1, Commission File No. 333-96025,
registering a total of 7,500,000 shares of our Common Stock and up to an
additional 1,125,000 shares pursuant to an over-allotment option, for a maximum
aggregate offering price of $245,812,500. Pursuant to the offering, we sold a
total of 8,568,000 shares to our underwriting syndicate. The offering was
completed on May 11, 2000, at an initial public offering price of $28.50 per
share, for gross proceeds totaling $244,188,000. After deducting underwriting
discounts of $17,050,320 and offering expenses, which we estimate to be
$1,200,000, we estimate our net proceeds from the offering to be $225,937,680.
Our managing underwriters for the offering were CIBC World Markets Corp.,
FleetBoston Robertson Stephens Inc., Warburg Dillon Read LLC, Adams, Harkness &
Hill, Inc. and KBC Securities Inc., acting as representatives of the several
underwriters named in the underwriting agreement.
Because the closing of our initial public offering of Common Stock
occurred after the three month period ended March 31, 2000, we did not use any
of the proceeds from the offering during the reporting period for this Form
10-Q. We expect that our use of these proceeds will be as described in the
prospectus to our Registration Statement.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits.
3.1 - Amended and Restated Certificate of Incorporation of
the Registrant, as amended, as currently in effect
(filed as Exhibit 3.1 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
3.2 - Bylaws of the Registrant, as currently in effect
(filed as Exhibit 3.2 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
4.1 - Specimen of Common Stock Certificate, $.01 par value,
of the Registrant (filed as Exhibit 4.1 to the
Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
4.2 - Warrant to Purchase 6,462 Shares of Common Stock, dated
November 1989, by and between the Registrant and
Phoenix Venture Incorporated (filed as Exhibit 4.2 to
the Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
12
10.1 - Form of Indemnification Agreement between the
Registrant and its officers and directors (filed as
Exhibit 10.1 to the Company's Registration Statement on
Form S-1 (Registration No. 333-96025) and
incorporated by reference herein).
10.2 - 1987 Stock Option Plan of the Registrant, as amended
(filed as Exhibit 10.2 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
10.3 - 1992 Non-employee Directors Stock Option Plan of the
Registrant (filed as Exhibit 10.3 to the Company's
Registration Statement on Form S-1 (Registration No.
333-96025) and incorporated by reference herein).
10.4 - 1997 Stock Plan of the Registrant (filed as Exhibit
10.4 to the Company's Registration Statement on Form
S-1 (Registration No. 333-96025) and incorporated by
reference herein).
10.5 - Lease of premises at 10301 Stella Link, Suite 110,
Houston, Texas, dated December 3, 1986, as amended
(filed as Exhibit 10.5 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
10.6 - Stock Purchase Agreement, dated July 14, 1987, by and
among the Registrant and Tse Wen Chang, Nancy T. Chang,
Alafi Capital Company, Shireen Alafi, Joseph Heskel,
Trustee for Christopher Alafi, and Invitron Corporation
(filed as Exhibit 10.6 to the Company's Registration
Statement on Form S-1 (Registration No.
333-96025) and incorporated by reference herein).
10.7 - License for Winter Patent, dated June 26, 1989, by and
between Medical Research Council and the Registrant
(filed as Exhibit 10.7 to the Company's Registration
Statement on Form S-1 (Registration No.
333-96025) and incorporated by reference herein).
10.8 - Amendment to the License for Winter Patent, dated
February 9, 1990, by and between Medical Research
Council and the Registrant (filed as Exhibit 10.8 to
the Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
10.9 - Development and Licensing Agreement, dated May 11,
1990, by and between the Registrant and Ciba-Geigy
Limited (filed as Exhibit 10.9 to the Company's
Registration Statement on Form S-1 (Registration No.
333-96025) and incorporated by reference herein).
10.10 - Term Sheet for Secured Loan, dated December 14, 1994,
by and between the Registrant and Ciba-Geigy Limited
(filed as Exhibit 10.10 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
10.11 - Chiron-PanGenetics Research and Development License
and Options for Commercial License, dated September
25, 1995, by and between PanGenetics, B.V., Panorama
Research, Inc. and Chiron Corporation (filed as
Exhibit 10.11 to the Company's Registration Statement
on Form S-1 (Registration No. 333-96025) and
incorporated by reference herein).
13
10.12 - Stock Purchase Agreement, dated as of March 12, 1998,
by and between the Registrant and the holders of
shares of PanGenetics, B.V. (filed as Exhibit 10.12
to the Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
10.13 - License Agreement, dated June 1, 1998, by and between
Biogen, Inc. and the Registrant (filed as Exhibit
10.13 to the Company's Registration Statement on Form
S-1 (Registration No. 333-96025) and incorporated by
reference herein).
10.14 - Outline of Terms for Settlement of the Litigations
Among Genentech, Inc., Genentech International, Ltd.,
the Registrant and Ciba-Geigy Limited Relating to
Anti-IgE Inhibiting Monoclonal Antibodies, dated July
8, 1996 (filed as Exhibit 10.14 to the Company's
Registration Statement on Form S-1 (Registration No.
333-96025) and incorporated by reference herein).
10.15 - Supplemental Agreement between the Registrant and
Ciba-Geigy Limited, dated July 8, 1996 (filed as
Exhibit 10.15 to the Company's Registration Statement
on Form S-1 (Registration No. 333-96025) and
incorporated by reference herein).
10.16 - Settlement and Cross-Licensing Agreement, dated July
8, 1996, by and between the Registrant and Genentech,
Inc. and Genentech International Limited (filed as
Exhibit 10.16 to the Company's Registration Statement
on Form S-1 (Registration No. 333-96025) and
incorporated by reference herein).
10.17 - Settlement and Participation Agreement, dated July 8,
1996, by and between the Registrant and F. Hoffman-La
Roche, Ltd., Hoffman-La Roche, Inc., Roche Holding
Ltd. and Roche Holdings, Inc. (filed as Exhibit 10.17
to the Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
10.18 - Patent License Agreement, dated June 30, 1998, by and
between Protein Design Labs, Inc. and the Registrant
(filed as Exhibit 10.18 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
10.19 - Amendment to Patent License Agreement, dated June 28,
1998, by and between Protein Design Labs, Inc. and
the Registrant (filed as Exhibit 10.19 to the
Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
10.20 - Research and License Agreement, dated April 21, 1999,
by and between the Registrant and Biovation Limited
(filed as Exhibit 10.20 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
10.21 - Material Transfer and Commercial Evaluation
Agreement, dated March 9, 1999, by and between Tanox,
Inc. and Biovation Limited (filed as Exhibit 10.21 to
the Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
14
10.22 - G-CSF Receptor Non-exclusive License Agreement, dated
January 11, 2000, by and between Immunex Corporation
and the Registrant (filed as Exhibit 10.22 to the
Company's Registration Statement on Form S-1
(Registration No. 333-96025) and incorporated by
reference herein).
10.23 - 2000 Non-Employee Directors' Stock Option Plan (filed
as Exhibit 10.23 to the Company's Registration
Statement on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein).
10.24 - Master Agreement, dated March 17, 2000, by and between
the Registrant and Protein Design Labs, Inc. (filed as
Exhibit 10.24 to the Company's Registration Statement
on Form S-1 (Registration No. 333-96025)
and incorporated by reference herein)
27 - Financial Data Schedule.
(b) Reports on Form 8-K.
No reports were required to be filed on Form 8-K during the three months
ended March 31, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
TANOX, INC.
Date: ________________________ By: _____________________________
Nancy T. Chang, Chief Executive Officer
Date: ________________________ By: _____________________________
David Duncan, Jr., Chief Financial Officer
15
INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION
- ----------- -----------
27 Financial Data Schedule
16